Under-Representation of Black and Hispanic Men in Metastatic Castration-Resistant Prostate Cancer Trials (2005-2021): A Call to Action

Le résumé fourni par la source

PURPOSE: Black men face the highest incidence and mortality rates of prostate cancer globally, including a disproportionate burden of metastatic castration-resistant prostate cancer (mCRPC). Despite this, clinical trials often fail to adequately represent the populations most affected. This study evaluates representation trends in mCRPC trials over a 17-year period. MATERIALS AND METHODS: We analyzed 33 phase III and IV mCRPC trials (2005-2021) registered on ClinicalTrials.gov. Data on race, ethnicity, and trial geography were extracted. Representation trends were assessed across time intervals and funding sources. A random-effects model was used to analyze pooled participant demographics. RESULTS: Of 33 trials (n = 28,746), 73% reported race and 42% reported ethnicity. Among trials with available data, 79.2% of participants were White, 10.8% were Asian, and only 3.8% were Black or African American. Hispanic participation was 6.7%. Notably, Black participation declined from 13.7% to 3% over the study period. Trial sites were predominantly located in North America and Europe, with no inclusion from Africa or the Caribbean. CONCLUSION: Racial and ethnic under-representation in mCRPC trials has remained profound and, in some cases, worsened, despite increasing awareness. These findings underscore a critical need for structural reforms in trial design, funding, and regulatory oversight to ensure equitable access and generalizability of prostate cancer therapies.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.